Jill Ohar to Severity of Illness Index
This is a "connection" page, showing publications Jill Ohar has written about Severity of Illness Index.
Connection Strength
0.621
-
Ohar JA, Sharma S, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sanjar S. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies. COPD. 2019 04; 16(2):133-139.
Score: 0.131
-
Ohar J, Tosiello R, Goodin T, Sanjar S. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Int J Chron Obstruct Pulmon Dis. 2019; 14:27-37.
Score: 0.127
-
Ohar J, Putcha N, Bradshaw M. Asthma-Chronic Obstructive Pulmonary Disease Overlap: Diagnostic and Management Challenges. J Fam Pract. 2018 10; 67(10 Suppl):S46-S51.
Score: 0.125
-
Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012 Feb 12; 72(3):301-8.
Score: 0.079
-
Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010 Jun; 31(3):321-33.
Score: 0.070
-
Ohar J, Sterling DA, Bleecker E, Donohue J. Changing patterns in asbestos-induced lung disease. Chest. 2004 Feb; 125(2):744-53.
Score: 0.045
-
Donohue JF, Ohar JA. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004; 1(3):152-60.
Score: 0.045